In summary (Table 1), despite the positive effects of MI administration in lung cancer models in animal trials and the evidence that MI reduces the levels of IL-6 and may decrease the activation of PI3K signaling pathways, the results obtained from trials conducted on humans do not support MI usage alone as a possible chemopreventive agent against lung cancer. Here, IL6 is linked to lung carcinoma.